Trevi Therapeutics to Present at 11th World Congress on Itch (WCI)

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced that Dr. Bill Forbes, Chief Development Officer, will present at the 11th World Congress on Itch on October 22-23, 2021. The session will focus on the challenges in itch research and the drug development perspective. Trevi is developing Haduvio (nalbuphine ER) for serious neurologically mediated conditions, including chronic pruritus and chronic cough. Haduvio has received Fast Track designation from the FDA for prurigo nodularis. The company aims to address unmet medical needs in itch management.

NEW HAVEN, Conn., Oct. 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Dr. Bill Forbes, Chief Development Officer, will present as part of a virtual viewpoint session at the 11^th World Congress on Itch (WCI) taking place from October 22-23, 2021. The group viewpoint session will cover the topic "What I miss in itch research" where Dr. Forbes will discuss the drug development perspective in itch, both progress, and remaining challenges.

Dr. Forbes, Chief Development Officer of Trevi, will participate in a virtual panel on 'What I Miss in Itch Research'

"I am looking forward to taking part in this virtual session at WCI alongside members of the itch community," said Bill Forbes, Pharm.D. "Itch is an important therapeutic area for research and I am happy to continue our conversations around itch as we explore potential therapies to address the large unmet need in these patients."

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

About Haduvio
Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not currently classified as a controlled substance by the DEA in the United States and by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Haduvio is an investigational therapy that has been granted Fast Track designation by the FDA for the proposed indication of reduction of moderate to severe pruritus in patients with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com

Media Contact 
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-present-at-11th-world-congress-on-itch-wci-301399622.html

SOURCE Trevi Therapeutics, Inc.

FAQ

What is Trevi Therapeutics presenting at the 11th World Congress on Itch?

Trevi Therapeutics will present on 'What I miss in itch research', focusing on drug development challenges in itch.

When is the 11th World Congress on Itch taking place?

The congress will take place on October 22-23, 2021.

What is Haduvio and its significance in Trevi's research?

Haduvio is an investigational therapy for treating serious neurologically mediated conditions, including chronic pruritus.

What status has Haduvio received from the FDA?

Haduvio has been granted Fast Track designation by the FDA for its potential use in treating moderate to severe pruritus.

Who is presenting for Trevi Therapeutics at the conference?

Dr. Bill Forbes, Chief Development Officer of Trevi Therapeutics, will present at the conference.